Oxybutynin for refractory hot flashes in cancer patients

Menopause

Volumn 14, Issue 3, 2007, Pages 505-509

  Sexton, Tracy ^a,b   Younus, Jawaid ^b   Perera, Francisco ^a,b   Kligman, Lyn ^a   Lock, Michael ^a,b  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b WESTERN UNIVERSITY   (Canada)

Author keywords

Breast cancer; Hot flashes; Oxybutynin

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MANDELIC ACID DERIVATIVE; OXYBUTYNIN;

ADULT; ARTICLE; CANADA; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; FEMALE; FOLLOW UP; HOSPITALIZATION; HOT FLUSH; HUMAN; MIDDLE AGED; NEOPLASM; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HOT FLASHES; HUMANS; MANDELIC ACIDS; MIDDLE AGED; NEOPLASMS; ONTARIO; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447265031     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/01.gme.0000243574.01441.3e     Document Type: Article

References (25)

1. Carpenter JS, Androykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999;26:1311-1317.
2. Carpenter JS. Hot flashes and their management following breast cancer. Semin Oncol Nurs 2000;16:214-225.
3. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
4. Walsh B, Schiff I. Vasomotor flushes. Ann N Y Acad Sci 1990;592:346-356.
5. Ginsburg SE. Hot flashes - physiology, hormonal therapy and alternative therapies. Obstet Gynecol Clin North Am 1994;21:381-391.
6. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22:293-312.
7. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
8. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
9. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
10. Perez DG, Loprinzi CL, Barton DL, et al. Pilot evaluation of mirtazapine for the treatment of hot flashes. J Support Oncol 2004;2:50-56.
11. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 2003;1:47-51.
12. Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347-352.
13. Bertelli G, Venturini M, Del Mastro L, et al. Intramuscular depot medroxyprogesterone versus oral megestrol for the control of postmenopausal hot flashes in breast cancer patients: a randomized study. Ann Oncol 2002;13:883-888.
14. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet Gynecol 1982;60:583-586.
15. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-158.
16. Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. CMAJ 1980;123:23-26.
17. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Obstet Gynecol 1987;156:561-565.
18. Pandya KJ, Raubertas RF, Flynn P, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Ann Intern Med 2000;132:788-793.
19. Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345.
20. Loprinzi L, Barton DL, Sloan JA, et al. Pilot evaluation of gabapentin for treating hot flashes. Mayo Clin Proc 2002;77:1159-1163.
21. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366:818-824.
22. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
23. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. Semin Reprod Med 2005;23:117-125.
24. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-262.
25. Chapple CR. Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 2000;55(Suppl 5A):33-46.